PRAX
Praxis Precision Medicines, Inc.
NASDAQ · Healthcare · Biotechnology · US
$351.88
−0.92%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.7x
Market Cap
$9.82B
MomentumView details →
1D Return
−0.92%
YTD Return
+19.35%
RSI (14)
49.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.7x
Market Cap
$9.82B
RSI (14)
49.5
MomentumView details →
1D Return
−0.92%
YTD Return
+19.35%
SummaryUpdated Jun 1, 2026
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company founded in 2015 and based in Boston, Massachusetts. The company went public in October 2020 and specializes in developing precision therapies for central nervous system disorders characterized by neuronal imbalance. Praxis focuses on genetically-defined patient populations and employs a precision medicine approach to address conditions including essential tremor, epilepsy, and depression. The company currently operates multiple clinical programs across various stages of development, with several candidates approaching potential regulatory submissions.
Similar companies
Latest newsMore news →
Praxis Precision Medicines, Inc. shares hit a new 52-week high of $391.64 during mid-day trading on Tuesday, last trading at $376.38 with volume of 581,487 shares.18d agoPraxis Precision Medicines is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, as both new drug applications remain under FDA review.29d ago